SCHEMBL1021673

SCHEMBL1021673

Cc1cccc(Cc2nsc(NCCN)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
HTR6 P50406 1/20 0.40
LTA4H P09960 1/20 0.39
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
MPO P05164 1/20 0.35
APP P05067 1/20 0.35
ZAP70 P43403 1/20 0.35
SYK P43405 1/20 0.35
KCNH2 Q12809 1/20 0.35
AURKB Q96GD4 1/20 0.35
IDO1 P14902 2/20 0.35
AR P10275 1/20 0.35
KARS1 Q15046 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020304 0.93 ALDH1A1 (0.40) TAAR1ALDH1A1LMNAHTR6LTA4H
SCHEMBL1018342 0.91 ALDH1A1 (0.40) TAAR1ALDH1A1LMNAHTR6LTA4H
SCHEMBL1022387 0.90 ALDH1A1 (0.39) TAAR1ALDH1A1LMNAHTR6LTA4H
SCHEMBL1020022 0.90 ALDH1A1 (0.39) TAAR1ALDH1A1LMNAHTR6LTA4H
SCHEMBL1021355 0.88 ALDH1A1 (0.43) TAAR1ALDH1A1LMNAHTR6LTA4H
SCHEMBL1021317 0.85 ALDH1A1 (0.39) TAAR1ALDH1A1LMNAHTR6LTA4H
SCHEMBL1021101 0.85 TAAR1 (0.42) TAAR1HTR6TLR8TLR7HTR2C
SCHEMBL1020496 0.84 TAAR1 (0.46) TAAR1HTR6LTA4HTLR8TLR7
SCHEMBL1024188 0.84 SMN1; SMN2 (0.37) TAAR1ALDH1A1LMNAHTR6LTA4H
SCHEMBL1018388 0.84 ALDH1A1 (0.37) ALDH1A1HTR6HRH4KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP TAAR1 2621/4885ALDH1A1 608/4885LMNA 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.